OSHANI PIERIS-STEELMAN: Open Payments
NPI 1841711488 · EDMOND, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,096 in 122 payments from 14 companies in 2025. Trend: 2023 $19 · 2024 $1,136 · 2025 $2,096
Food & beverage: $2,096
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 27 | $445 |
| ABBVIE INC. | 30 | $332 |
| Alkermes, Inc. | 12 | $233 |
| Janssen Pharmaceuticals, Inc | 12 | $205 |
| Otsuka America Pharmaceutical, Inc. | 10 | $204 |
| Teva Pharmaceuticals USA, Inc. | 8 | $181 |
| E.R. Squibb & Sons, L.L.C. | 8 | $153 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| Vanda Pharmaceuticals Inc. | 2 | $58 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $47 |
Products named: CAPLYTA, VRAYLAR, COBENFY, REXULTI, SPRAVATO, ARISTADA, AUSTEDO XR, LYBALVI.
Industry payments across OK — which companies pay providers there.
